(Q77306461)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

title

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

main subject

phase I clinical trial

1 reference

1 reference

M L Rothenberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

A Sharma

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

G R Weiss

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

M A Villalona-Calero

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

J R Eckardt

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

C Aylesworth

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

M A Kraynak

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

D A Rinaldi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

G I Rodriguez

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

H A Burris

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

S G Eckhardt

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

C D Stephens

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

K Forral

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

S J Nicol

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

D D Von Hoff

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

publication date

1 July 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

page(s)

733-738

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine)

4 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008286908930

7 January 2021

Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008286908930

7 January 2021

Clinical, toxicological and pharmacological aspects of gemcitabine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008286908930

7 January 2021

In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008286908930

7 January 2021

A role for paclitaxel in the combination chemotherapy of acute myeloblastic leukaemia: preclinical cell culture studies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008286908930

7 January 2021

https://api.crossref.org/works/10.1023%2FA%3A1008286908930

1 reference

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008286908930

7 January 2021

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008286908930

7 January 2021

Identifiers

DOI

10.1023/A:1008286908930

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9739439%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference